August 21, 2014 5:44 PM ET

Biotechnology

Company Overview of Visionary Pharmaceuticals, Inc.

Company Overview

Visionary Pharmaceuticals, Inc., a biotechnology company, develops small molecule therapies for unmet medical needs in cancer and inflammation. It also specializes in translating chemical entities to the clinic and delivers nuclear receptor modulators to treat rheumatoid arthritis, multiple sclerosis, psoriasis, COPD, and cancer. The company’s product portfolio includes immunomodulators of Th17 T-helper lymphocytes for inflammation and Warburg effect inhibitors for cancer. It focuses on developing potent and selective antagonists of the retinoic acid receptor-related orphan nuclear receptor ROR?, a specific isoform expressed in lymphocytes; and novel inhibitors that modulate the aberrant met...

11555 Sorrento Valley Road

Suite A

San Diego, CA 92121-1331

United States

Founded in 2010

Phone:

858-335-8120

Key Executives for Visionary Pharmaceuticals, Inc.

Co-Founder
Co-Founder
Chief Financial Officer
Compensation as of Fiscal Year 2014.

Visionary Pharmaceuticals, Inc. Key Developments

Visionary Pharmaceuticals, Inc. and BioBlocks, Inc. Announce Drug Discovery Collaboration Targeting Serum and Glucocorticoid-Regulated Kinase 1

Visionary Pharmaceuticals, Inc. and BioBlocks, Inc. announced the companies have established a collaboration for the discovery and development of novel small molecule inhibitors of Serum and Glucocorticoid-Regulated Kinase 1 (SGK1). This kinase has been implicated in tumorigenesis of various solid tumors including non-small cell lung cancer, breast, prostate and colorectal cancer. Importantly, SGK1 is a critical mediator of chemoresistance in triple negative breast cancer and other cancers. Together these cancers represent a significant unmet medical need. The parties will combine their respective technologies and expertise to generate superior leads in novel patentable space. BioBlocks' contribution includes its Leap-to-Lead(TM) small molecule lead discovery platform comprised of its proprietary physical fragment libraries and the Syntheverse(TM) virtual library, a vast database of feasible molecules providing solutions for fragment evolution. Visionary's contributions include its BindingSIGHTS(TM) technology platform comprised of a suite of computational algorithms and knowledge engine which identifies critical inhibitory hotspots in kinase enzyme active sites.

Visionary Pharmaceuticals, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013 04:30 PM

Visionary Pharmaceuticals, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013 04:30 PM. Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States.

Similar Private Companies By Industry

Company Name Region
Aurora Analytics, LLC United States
Precision BioSciences, Inc. United States
RadioPharmacy Investors, LLC United States
AntiCancer, Inc. United States
Traxxsson, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Visionary Pharmaceuticals, Inc., please visit www.visionarypharmaceutical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.